• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role

    11/8/23 9:50:00 AM ET
    $BMY
    $ILMN
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BMY alert in real time by email

    New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal of precision medicine.

    According to Straits Research, "North America is dominating the market with the highest revenue and is expected to reach USD 97.32 billion in 2030, growing at a CAGR of 9.7% during the forecast period,"

    Download Free Sample Report PDF @ https://straitsresearch.com/report/precision-medicine-market/request-sample

    Key Drivers

    DNA sequencing technology has undergone significant technological advancements, which have paved the way for a deeper understanding of some diseases like cancer. Depending on the genetic profiles of those individuals, the advancements have made it possible to develop treatments that are better suited to them. Patients with breast, lung, or colorectal cancer who have undergone genetic testing as part of routine patient care can measure this molecular transformation of medicine. As a result, the process's accuracy and the time required to finish it have increased. With the collection of more medical data, there has been an increase in understanding of how the treatment a patient receives affects the patient's overall health. It is possible to use precision medicine for preventive care when interventions target disease risk factors to lower the disease risk. One example of this would be the treatment of high blood pressure to prevent patients from experiencing heart attacks or strokes.

    Growth Opportunities

    Most precision medicine providers focus on developed markets, leaving emerging markets untapped. Large populations at risk for diseases requiring gene sequencing in China, India, Australia, the Middle East, and Africa present an opportunity to expand the precision medicine market. Genetics and precision medicine have made significant progress in developing countries over the past decade regarding regulations, product approvals, and implementation of novel methods and procedures in healthcare.

    Searching for mendelian germline genetic mutations, such as those in cancer genetics, is likely the first step for emerging nations' public healthcare systems. Private healthcare investment funds help small innovative players develop new genetic tests in emerging regions. Developing nations' proper and uncomplicated approval of GINA helped ban genetic discrimination in health insurance and employment. This creates a modern and humanized genomic medicine environment in the country.

    Regional Analysis

    The North American segment dominates the market with the highest revenue, and The United States dominates North America's precision medicine market. Advanced research and development in molecular diagnostics and targeted therapeutics have significantly aided our understanding of the biology of various infectious diseases and forms of cancer, such as lung cancer, breast cancer, and colorectal cancer.

    Several well-established diagnostics manufacturers in North America are focusing on expanding their portfolios of NGS-based molecular diagnostics and collaborating with service providers and pharmaceutical behemoths to co-market molecular diagnostics solutions alongside their complementary precision medicine solutions. In addition, the U.S. government finances new molecular diagnostics and precision medicine start-ups.

    Key Highlights

    • The global precision medicine market size is projected to reach USD 280.67 billion by 2030, growing at a CAGR of 11.12% during the forecast period (2022–2030).
    • Based on the ecosystem, the global precision medicine market is segmented into sciences, precision diagnostics, precision therapeutics, and digital health and information technology. The precision therapeutics segment is dominating the market and is expected to grow at a CAGR of 11.62% during the forecast period.
    • Based on application, the global precision medicine market is segmented into oncology, neurology/psychiatry, infectious diseases, gastroenterology, cardiovascular, endocrinology, rheumatology, etc. The oncology segment is the most dominant and is expected to grow at a CAGR of 11.21% during the forecast period.

    Competitive Analysis

    The global precision medicine market's major key players are Bristol-Myers Squibb Company, Illumina, Inc., Pacific Biosciences of California, Inc., AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Premaitha Health plc, QIAGEN N.V., Johnson and Johnson, and Asuragen, Inc.

    Market News

    • May 2022- Illumina Introduced New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy. The first companion diagnostic claim for Illumina's TruSightTM Oncology Comprehensive (EU) test enables targeted therapy for patients with NTRK fusion cancer using Bayer's VITRAKVI® (larotrectinib).
    • May 2022- Illumina and Allegheny Health Network Assessed In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care. Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving Western Pennsylvania, have partnered to evaluate the impact of in-house comprehensive genomic profiling (CGP) on patient care.
    • June 2022- Bristol Myers Squibb Acquired Turning Point Therapeutics, a Leading Precision Oncology Company. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) have announced a definitive merger agreement.

    Global Precision Medicine Market: Segmentation

    By Ecosystem

    • Applied Sciences
    • Precision Diagnostics
    • Precision Therapeutics
    • Digital Health and Information Technology

    By Application

    • Oncology
    • Neurology/psychiatry
    • Infectious diseases
    • Gastroenterology
    • Cardiovascular
    • Endocrinology
    • Rheumatology

    By Regions

    • North America
    • Europe
    • Asia-Pacific
    • Rest-of-the-World (ROW)

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/precision-medicine-market/segmentation

    About Straits Research Pvt Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, specially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    For more information on your target market, please contact us below:

    Phone: +1 646 480 7505 (the U.S.)

    +91 8087085354 (APAC)

    +44 208 068 9665 (the U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY
    $ILMN
    $TPTX

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Illumina Inc.
    $ILMN
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    Illumina Inc.
    $ILMN
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Illumina Inc.
    $ILMN
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    $ILMN
    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Shibutani Hiroshi Chris

      3 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/16/25 6:47:45 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. gifted 62,719 shares and received a gift of 62,719 shares, closing all direct ownership in the company (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/16/25 6:43:52 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Corporate Affairs Short Bartie Wendy converted options into 8,040 shares and covered exercise/tax liability with 3,334 shares (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/4/25 5:37:59 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $ILMN
    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Illumina with a new price target

      Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

      3/4/25 8:10:42 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $BMY
    $ILMN
    $TPTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care